title: Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
abstract: Twelve patients with levodopa-induced dyskinesias were treated with continuous subcutaneous apomorphine. A markedly significant reduction in peak dose dyskinesias occurred over a two-year follow-up.
authors.affiliation: 1st Department of Neurology, Masaryk University, St. Anne Hospital, Brno, Czech Republic. pkanov@med.muni.cz
authors.forename: Petr
authors.initials: P
authors.lastname: Kanovský
authors.forename: Dagmar
authors.initials: D
authors.lastname: Kubová
authors.forename: Martin
authors.initials: M
authors.lastname: Bareš
authors.forename: Hana
authors.initials: H
authors.lastname: Hortová
authors.forename: Hana
authors.initials: H
authors.lastname: Streitová
authors.forename: Ivan
authors.initials: I
authors.lastname: Rektor
authors.forename: Vladimír
authors.initials: V
authors.lastname: Znojil
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001058:Apomorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa; D001058:Apomorphine